Loading clinical trials...

COMPLETEDPHASE3

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone

NCT00039026•AstraZeneca

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.

Eligibility

Age

16 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects with Type 2 diabetes mellitus
•Treated with a sulfonylurea at defined doses for at least 3 months prior to screening
•BMI= 27-45 kg/m2
•HbA1c value between 7.5% and 11%

Exclusion Criteria

•Treated with oral anti-diabetic medications other than a sulfonylurea within 3 months of screening
•Patients treated previously with AC2993
•Patients presently treated with insulin

Locations (126)

Pinnacle Research Group

Anniston, Alabama, United States

Parkway Medical Center

Birmingham, Alabama, United States

Alabama Clinical Therapeutics

Birmingham, Alabama, United States

Eclectic Family Care

Eclectic, Alabama, United States

Winston Physician Services

Haleyville, Alabama, United States

Simon Williamson Clinic

Hueytown, Alabama, United States

Extended Arm Physicians/ Southern Drug

Montgomery, Alabama, United States

Southern Drug Research Network

Tallassee, Alabama, United States

Clinic of Physicians and Surgeons, Ltd.

Mesa, Arizona, United States

ANA Ventures, LLC

Mesa, Arizona, United States

Key Dates

Start Date

February 1, 2002

Primary Completion Date

August 1, 2003

Completion Date

August 1, 2003

Last Updated

February 24, 2015

Enrollment

377

ACTUAL participants

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Interventions

AC2993

DRUG

AC2993

DRUG

Placebo

DRUG

Placebo

DRUG

Technology Intensified Diabetes Education Study in African Americans

NCT02088658

Diabetes Mellitus, Type 2Diabetes Mellitus, Adult-Onset+3 more

View study

COMPLETEDPHASE1

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163

Diabetes Mellitus, Non-Insulin-DependentHypertriglyceridemia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Inclusion Criteria

Exclusion Criteria

Technology Intensified Diabetes Education Study in African Americans

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

Diabetes Prevention Program

Effect of Gelofusine on GLP1-receptor Imaging

Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)